The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $48.28

Today's change+1.26 +2.68%
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Alnylam Pharmaceuticals Inc

Nasdaq: ALNY
Last

(U.S.) $48.28

Today's change+1.26 +2.68%
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.

Alnylam Pharmaceuticals Inc Hits New 50-day High

Alnylam Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$1.26 or 2.68% to (U.S.)$48.28 and setting a new 50-day high. Over the last five days, shares have gained 5.95% and 28.95% year to date. Shares have underperformed the S&P 500 by 48.54% during the last year.

Key company metrics

  • Open(U.S.) $46.86
  • Previous close(U.S.) $47.02
  • High(U.S.) $48.45
  • Low(U.S.) $45.97
  • Bid / Ask(U.S.) $47.65 / (U.S.) $49.35
  • YTD % change+28.95%
  • Volume799,181
  • Average volume (10-day)964,701
  • Average volume (1-month)950,728
  • Average volume (3-month)1,346,641
  • 52-week range(U.S.) $31.38 to (U.S.) $80.11
  • Beta2.71
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.79
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-869.63%

Although this company's net profit margin is negative, it is above the industry average and implies that Alnylam Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.16%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue171497
Total other revenue--------
Total revenue171497
Gross profit--------
Total cost of revenue--------
Total operating expense133120101117
Selling / general / administrative28221821
Research & development105988396
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-115-107-92-110
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-113-104-90-103
Income after tax-113-104-90-103
Income tax, total0--00
Net income-113-104-90-103
Total adjustments to net income--------
Net income before extra. items-113-104-90-103
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-113-104-90-103
Inc. avail. to common incl. extra. items-113-104-90-103
Diluted net income-113-104-90-103
Dilution adjustment--------
Diluted weighted average shares86868685
Diluted EPS excluding extraordinary itemsvalue per share-1.32-1.21-1.05-1.21
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-1.32-1.21-1.05-1.21